Compare HPP & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HPP | EVMN |
|---|---|---|
| Founded | 1997 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 553.0M | 892.4M |
| IPO Year | N/A | N/A |
| Metric | HPP | EVMN |
|---|---|---|
| Price | $6.06 | $23.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | $15.45 | ★ $43.29 |
| AVG Volume (30 Days) | ★ 1.2M | 299.2K |
| Earning Date | 05-06-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.09 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.67 | $13.89 |
| 52 Week High | $14.95 | $33.20 |
| Indicator | HPP | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 37.18 | 46.88 |
| Support Level | $5.55 | $21.86 |
| Resistance Level | $7.99 | $33.20 |
| Average True Range (ATR) | 0.47 | 2.07 |
| MACD | -0.02 | -0.39 |
| Stochastic Oscillator | 12.07 | 35.11 |
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.